Certain RGCC tests look for circulating tumor cells, often called CTCs, and assess their number or cellular markers. The information included varies by test.

Your provider explains what the selected panel measures and how its findings relate to your existing records. A result must be interpreted alongside your diagnosis, imaging, pathology, and other relevant tests.

Some RGCC panels assess how collected cells respond to selected chemotherapy drugs, targeted agents, or natural substances under laboratory conditions.

A laboratory response does not establish that a substance will be safe or effective for you. Findings require careful clinical interpretation and should not be used alone to choose or change cancer treatment.

Your consultation is an opportunity to review your diagnosis, treatment history, medications, supplements, and prior test results. The next step is deciding whether a specific test is appropriate for your situation.

If testing is selected, your provider will explain sample collection, preparation, expected timing, and fees. Do not pause prescribed treatment or change medications to prepare for testing unless your treating clinician directs you to do so.

Once results are available, your provider reviews the findings with you, explains their limitations, and helps identify questions to discuss with your oncology team.

Any further evaluation or follow-up testing should have a clear clinical purpose. Decisions about cancer treatment remain part of your care with your treating specialists.

Timing: Sample collection requirements and laboratory turnaround depend on the selected test. Ask the Avita team about the expected schedule and total cost before proceeding.